GKV Capital Management Co. Inc. Takes Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

GKV Capital Management Co. Inc. purchased a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 3,738 shares of the pharmaceutical company's stock, valued at approximately $1,505,000.

A number of other large investors have also recently bought and sold shares of the business. Advisory Resource Group boosted its holdings in shares of Vertex Pharmaceuticals by 3.2% during the 3rd quarter. Advisory Resource Group now owns 1,970 shares of the pharmaceutical company's stock worth $916,000 after buying an additional 61 shares during the period. Anchor Investment Management LLC grew its position in shares of Vertex Pharmaceuticals by 1,352.3% in the third quarter. Anchor Investment Management LLC now owns 1,583 shares of the pharmaceutical company's stock valued at $736,000 after purchasing an additional 1,474 shares during the last quarter. World Investment Advisors LLC acquired a new position in shares of Vertex Pharmaceuticals during the 3rd quarter worth about $24,280,000. Wilmington Savings Fund Society FSB bought a new stake in Vertex Pharmaceuticals during the 3rd quarter valued at approximately $2,187,000. Finally, Destination Wealth Management increased its position in Vertex Pharmaceuticals by 4.5% in the 3rd quarter. Destination Wealth Management now owns 3,361 shares of the pharmaceutical company's stock worth $1,563,000 after buying an additional 144 shares during the period. 90.96% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on VRTX. Scotiabank boosted their target price on shares of Vertex Pharmaceuticals from $433.00 to $450.00 and gave the stock a "sector perform" rating in a research report on Tuesday, February 11th. Wells Fargo & Company downgraded Vertex Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $460.00 target price on the stock. in a research report on Thursday, January 30th. Canaccord Genuity Group raised Vertex Pharmaceuticals from a "sell" rating to a "hold" rating and upped their price target for the company from $408.00 to $424.00 in a report on Tuesday, February 11th. Piper Sandler decreased their price objective on Vertex Pharmaceuticals from $535.00 to $533.00 and set an "overweight" rating on the stock in a report on Monday, January 27th. Finally, William Blair restated an "outperform" rating on shares of Vertex Pharmaceuticals in a research note on Friday, January 31st. Ten analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $512.41.

Vertex Pharmaceuticals Stock Performance

VRTX stock traded up $3.21 during mid-day trading on Friday, hitting $489.10. 1,205,462 shares of the company were exchanged, compared to its average volume of 1,330,372. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. The business has a 50 day simple moving average of $486.76 and a 200-day simple moving average of $465.23. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88. The stock has a market capitalization of $125.60 billion, a PE ratio of -222.32, a price-to-earnings-growth ratio of 2.11 and a beta of 0.50.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. On average, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 244 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total transaction of $111,034.64. Following the completion of the transaction, the executive vice president now directly owns 67,695 shares in the company, valued at $30,805,286.70. The trade was a 0.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP David Altshuler sold 3,231 shares of the firm's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $500.00, for a total value of $1,615,500.00. Following the completion of the sale, the executive vice president now directly owns 26,512 shares in the company, valued at approximately $13,256,000. This represents a 10.86 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 4,315 shares of company stock worth $2,121,012. Company insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.